[go: up one dir, main page]

NZ730982B2 - Use of cannabinoids in the treatment of epilepsy - Google Patents

Use of cannabinoids in the treatment of epilepsy Download PDF

Info

Publication number
NZ730982B2
NZ730982B2 NZ730982A NZ73098215A NZ730982B2 NZ 730982 B2 NZ730982 B2 NZ 730982B2 NZ 730982 A NZ730982 A NZ 730982A NZ 73098215 A NZ73098215 A NZ 73098215A NZ 730982 B2 NZ730982 B2 NZ 730982B2
Authority
NZ
New Zealand
Prior art keywords
cbd
cannabidiol
treatment
syndrome
atonic seizures
Prior art date
Application number
NZ730982A
Other versions
NZ730982A (en
Inventor
Orrin Devinsky
Geoffrey Guy
Alice Mead
Stephen Wright
Original Assignee
GW Research Limited
Filing date
Publication date
Priority claimed from GB1418171.3A external-priority patent/GB2531282A/en
Application filed by GW Research Limited filed Critical GW Research Limited
Priority to NZ768001A priority Critical patent/NZ768001B2/en
Publication of NZ730982A publication Critical patent/NZ730982A/en
Publication of NZ730982B2 publication Critical patent/NZ730982B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Claims (8)

1. Use of cannabidiol (CBD) in the manufacture of a medicament for the treatment of atonic seizures in Lennox-Gastaut syndrome wherein the CBD is in the form of a highly purified 5 extract of cannabis which comprises at least 98% (w/w) CBD or is present as a synthetic compound.
2. The use of cannabidiol (CBD) as claimed in claim 1, wherein the atonic seizures are treatment-resistant.
3. The use of cannabidiol (CBD) as claimed in claim 1 or 2, wherein the CBD is to be used in combination with one or more concomitant anti-epileptic drugs (AED).
4. The use of cannabidiol (CBD) as claimed in any one of claims 1-3, wherein the extract 15 comprises less than 0.15% THC.
5. The use of cannabidiol (CBD) as claimed in any one of claims 1-4, wherein the extract further comprises up to 1% CBDV. 20
6. The use of cannabidiol (CBD) as claimed in claim 3, wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin. 25
7. The use of cannabidiol (CBD) as claimed in any one of claims 1-6, wherein the dose of CBD is greater than 5 mg/kg/day.
8. A use according to claim 1, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying 30 figures.
NZ730982A 2015-10-14 Use of cannabinoids in the treatment of epilepsy NZ730982B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ768001A NZ768001B2 (en) 2015-10-14 Use of cannabinoids in the treatment of epilepsy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1418171.3A GB2531282A (en) 2014-10-14 2014-10-14 Use of cannabinoids in the treatment of epilepsy
PCT/GB2015/053028 WO2016059403A1 (en) 2014-10-14 2015-10-14 Use of cannabinoids in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
NZ730982A NZ730982A (en) 2024-05-31
NZ730982B2 true NZ730982B2 (en) 2024-09-03

Family

ID=

Similar Documents

Publication Publication Date Title
IL276217B1 (en) Use of cannabinoids in the treatment of epilepsy
MX2023003337A (en) Use of cannabinoids in the treatment of epilepsy.
RU2020119390A (en) THE USE OF CANNABINOIDS IN THE TREATMENT OF SEX ASSOCIATED WITH LENNOX-GASTO SYNDROME
FI3641819T3 (en) THE USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROSIS SCLEROSIS COMPLEX
MX386086B (en) Cannabis composition
MX379255B (en) USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY.
RU2012103603A (en) APPLICATION OF ONE OR COMBINATION OF PHYTOCANNABINOIDS FOR THE TREATMENT OF EPILEPSY
EA201490711A8 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)
MX2020007960A (en) Methods of purifying cannabinoids using liquid:liquid chromatography.
NZ629136A (en) Phytocannabinoids in the treatment of cancer
GB201111261D0 (en) Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
TN2014000195A1 (en) 2-THIOPYRIMIDINONES
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
EP2878305A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES MEDIATED BY STAT-3 CONTAINING AN EXTRACT OR A FRACTION OF SALVIA PLEBEIA R. BR. AS ACTIVE INGREDIENT
PH12017502145A1 (en) Composition and uses thereof
WO2013100718A3 (en) Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
NZ730982B2 (en) Use of cannabinoids in the treatment of epilepsy
NZ768001B2 (en) Use of cannabinoids in the treatment of epilepsy
WO2015082590A3 (en) Bis-mmf derivatives
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
NZ727509B2 (en) Use of cannabinoids in the treatment of epilepsy
NZ727509A (en) Use of cannabinoids in the treatment of epilepsy
PL409542A1 (en) Pharmaceutical combination and compositions against neuritis
NZ765223B2 (en) Use of cannabinoids in the treatment of epilepsy